Why TIL Stock slipped -0.37% Today — RQD Quant Desk Flash

Per the Roarable RQD rating, TIL scores 39 out of 100 and receives a letter grade of D-, with the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars, the fundamental cash engine scores 9 out of 20 (ROIC -35%; FCF yield 0%), indicating the business is not currently generating returns on capital or free cash flow. Whale 13F flow scores 7 out of 20, reflecting institutional accumulation and options positioning that the rating characterizes as weak. Insider conviction scores 5 out of 20, based on SEC Form 4 and Congressional PTR cluster flow. Macro regime fit scores 8 out of 20 with a beta of 1.0 and noted sector sensitivity. Forensic balance sheet scores 10 out of 20, supported by an Altman Z of 2.5, a Piotroski F of 3 out of 9, and a debt-to-equity of 0.5.

For a prospective investor, the rating points to a company whose valuation rests on future outcomes rather than current earnings or cash generation. The pillar scores imply limited near-term upside drivers from operations, weak signals from insider and institutional behavior, and a balance sheet that the rating treats as vulnerable rather than robust. Valuation tradeoffs are sharp: with no reported revenue and negative operating income in each period shown, traditional earnings-based multiples are not meaningful here, and the market capitalization of $46.3M sits against cumulative reported losses. This is an educational read of the rating framework, not personalized advice.

Instil Bio Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry, per the profile. The source data does not describe its products, customers, or revenue model. The FY 2025 and FY 2024 financials report $0.0M in revenue, which is the only available indication of commercial activity in the reported periods. Source data does not describe how the company generates or intends to generate revenue.

Per the SEC financials, reported operating and net losses narrowed from $-159.2M operating income in FY 2023 to $-78.6M in FY 2025, while cash declined from $8.8M in FY 2024 to $6.6M in FY 2025. Gross, operating, and net margins are each 0% in the market data, and ROIC is -35%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 3 out of 9, both as reported in the Roarable RQD rating. Debt-to-equity is 0.5 per the same rating, though the reported debt line is N/A in the financial table.

The news wire contains six items, all tagged as market wire and rated yellow, and all summarized by third-party outlets as market-action reports covering TIL's price moves, institutional positioning, and fundamentals. Headlines reference a session decline to $5.70 with a $5.42 support level and a later rise to $5.84, along with liquidity-mapping and top-loser/largest-company list items. The summaries are generic and do not describe a specific fundamental catalyst such as a trial result, partnership, or financing. Risk watch items are the reported losses, the cash decline, and the stock's position near the low end of its 52-week range. The Butterfly Supply-Chain Graph reports no proprietary signals.

Per the Butterfly Supply-Chain Graph, supply_chain is NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore not available in source data beyond the sector classification itself (Health Care, Biological Products). Investors should note the absence of mapped links means this analysis cannot identify specific supplier, customer, or partner exposure.

• What products or development programs does the company have, and what is their stage and timeline?
• What is the cash runway given $6.6M in reported cash against FY 2025 free cash flow of $-36.6M, and how is the gap being financed?
• What is the debt structure, given the reported debt line is N/A while debt-to-equity is cited as 0.5?
• What explains the reported change from $-156.1M net income in FY 2023 to $-71.4M in FY 2025?
• Who holds the shares and how has institutional and insider ownership changed over time?